|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8740 EUR | +1.86% |
|
-2.35% | -43.10% |
| Jun. 18 | AB Science Secures US Patent for Prostate Cancer Therapy | MT |
| Jun. 18 | AB Science Secures New U.S. Patent for Masitinib |  |
Company Valuation: AB Science
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 332.2 | 180.9 | 57.55 | 112 | 66.9 | - | - |
| Change | - | -45.55% | -68.19% | 94.7% | -40.3% | - | - |
| Enterprise Value (EV) | 332.2 | 180.9 | 57.55 | 112 | 66.9 | 66.9 | 66.9 |
| Change | - | -45.55% | -68.19% | 94.7% | -40.3% | 0% | 0% |
| P/E | -24.4x | -17.8x | -5.88x | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0.6x | 0.2x | - | - | - | - |
| Capitalization / Revenue | - | 187x | 53.7x | 95.4x | 55.7x | 51.5x | 41.8x |
| EV / Revenue | - | 0x | 0x | 0x | 55.7x | 51.5x | 41.8x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | 0x | -10.3x | -10.5x | - |
| EV / FCF | - | -0x | - | -0x | -10.5x | -18.6x | -17.2x |
| FCF Yield | - | -9.52% | - | -4.08% | -9.57% | -5.38% | -5.83% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.29 | -0.2 | -0.15 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 0.97 | 1.072 | 1.174 | 1.2 | 1.3 | 1.6 |
| EBITDA | - | -11.16 | -5.416 | - | - | - | - |
| EBIT 1 | - | -13.43 | -6.083 | 0.639 | -6.5 | -6.4 | - |
| Net income | -13.62 | -10.05 | -7.831 | - | - | - | - |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 7.0900 | 3.5550 | 0.8820 | 1.5360 | 0.8740 | 0.8740 | 0.8740 |
| Nbr of stocks (in thousands) | 46,861 | 50,891 | 65,248 | 72,947 | 76,539 | - | - |
| Announcement Date | 3/1/23 | 5/15/24 | 5/13/25 | 5/13/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 76.29M | |
| 57.4x | 5.26x | 21.56x | 2.6% | 318B | |
| 24.6x | 3.37x | 12.01x | 1.6% | 72.22B | |
| 11.13x | 5.69x | 8.76x | - | 8.89B | |
| 16.56x | 2.09x | 7.18x | 2.7% | 8.25B | |
| 22.11x | 6.27x | 17.83x | -.--% | 4.23B | |
| 30.95x | 5.89x | 16.85x | - | 3.58B | |
| 36.87x | 2.08x | 25.44x | 0.84% | 3.23B | |
| 108.09x | - | - | -.--% | 2.72B | |
| Average | 38.47x | 4.38x | 15.66x | 1.29% | 46.77B | |
| Weighted average by Cap. | 49.58x | 4.87x | 19.31x | 2.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AB Stock
- Valuation AB Science
Select your edition
All financial news and data tailored to specific country editions
